Xconomy Seattle

Cell Therapeutics Dumps $52.9M Debt

Luke Timmerman6/19/09

Cell Therapeutics (NASDAQ: CTIC), the Seattle-based developer of cancer drugs, said today it has gotten rid of $52.9 million worth of debt, or about 44 percent of its total debtload. The company had sought to unload all of its $118.9 million in debt, but ended up paying out $7.1 million in cash and 24.2 million shares in exchange for the smaller amount of debt relief.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.

Related Topics

Add Your Thoughts

You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted.
By clicking "Publish," you are agreeing to these Terms and Conditions.

Links to This Post

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.